Freeform Search

Database: US Pre-Grant Publication Full-Text Database
US Patents Full-Text Database
US OCR Full-Text Database
EPO Abstracts Database
JPO Abstracts Database
Derwent World Patents Index
IBM Technical Disclosure Bulletins

Term: L6 with l3

Display: 10 **Documents in Display Format:** - **Starting with Number** 1

Generate: ○ **Hit List** ◉ **Hit Count** ○ **Side by Side** ○ **Image**

Search Clear Interrupt

Search History

DATE: Thursday, January 22, 2004 Printable Copy Create Case

Set Name side by side	Query	Hit Count	Set Name result set
DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI; PLUR=YES; OP=ADJ			
L7	L6 with l3	24	L7
L6	plasmid or gene therapy or nucleic or DNA	229527	L6
L5	L4 with l3	8	L5
L4	fusogenic or conjugated or complexed or covalently	188336	L4
L3	L2 with l1	242	L3
L2	cationic or polycationic	156122	L2
L1	polyhistidine or poly-L-histidine or histidine	41549	L1

END OF SEARCH HISTORY

L7: Entry 19 of 24 File: USPT Apr 18, 2000

DOCUMENT-IDENTIFIER: US 6051429 A
** See image for Certificate of Correction **
TITLE: Peptide-enhanced cationic lipid transfections

CLAIMS:

52. The method of claim 51 wherein said nucleic acid-binding group comprises the cationic peptide sequence (Uaa).sub.u where each amino acid, Uaa, in the sequence, independently of any other amino acid in the sequence can be lysine, arginine, ornithine, homoarginine, or histidine and where u is an integer from 1 to about 20.

56. The method of claim 55 wherein said nucleic acid-binding group comprises the cationic peptide sequence (Uaa).sub.u where each amino acid, Uaa, in the sequence, independently of any other amino acid in the sequence can be lysine, arginine, ornithine, homoarginine, histidine, glycine or proline and where u is an integer from 1 to about 20.

66. The method of claim 62 wherein said nucleic acid-binding group comprises the cationic peptide sequence (Uaa).sub.u where each amino acid, Uaa, in the sequence, independently of any other amino acid in the sequence can be lysine, arginine, ornithine, homoarginine, or histidine and where u is an integer from 1 to about 20.

70. The method of claim 69 wherein said nucleic acid-binding group comprises the cationic peptide sequence (Uaa).sub.u where each amino acid, Uaa, in the sequence, independently of any other amino acid in the sequence can be lysine, arginine, ornithine, homoarginine, histidine, glycine or proline and where u is an integer from 1 to about 20.

74. The method of claim 73 wherein said nucleic acid-binding group comprises the cationic peptide sequence (Uaa).sub.u where each amino acid, Uaa, in the sequence, independently of any other amino acid in the sequence can be lysine, arginine, ornithine, homoarginine, or histidine and where u is an integer from 1 to about 20.

89. The method of claim 88 wherein said nucleic acid-binding group comprises the cationic peptide sequence (Uaa).sub.u where each amino acid, Uaa, in the sequence, independently of any other amino acid in the sequence can be lysine, arginine, ornithine, homoarginine, or histidine and where u is an integer from 1 to about 20.

First Hit

☐ Generate Collection

L7: Entry 14 of 24 File: PGPB Jul 5, 2001

PGPUB-DOCUMENT-NUMBER: 20010006817
PGPUB-FILING-TYPE: new-utility
DOCUMENT-IDENTIFIER: US 20010006817 A1

TITLE: CELL DELIVERY COMPOSITIONS

PUBLICATION-DATE: July 5, 2001

US-CL-CURRENT: 435/440; 435/325, 435/455, 435/456, 435/458, 435/6, 435/69.1, 435/91.1, 514/44, 530/300, 530/350, 536/23.1

APPL-NO: 09/ 251783 [PALM]
DATE FILED: February 17, 1999
CONTINUED PROSECUTION APPLICATION: CPA

RELATED-US-APPL-DATA:
Application is a non-provisional-of-provisional application 60/075272, filed February 19, 1998,

PRIORITY INFORMATION

[0001] This application claims priority to the co-pending provisional application No. 60/075,272 entitled "Cell Delivery Compositions" filed on Feb. 19, 1998, which is incorporated in its entirety by reference.

L7: Entry 16 of 24 File: USPT Oct 22, 2002

DOCUMENT-IDENTIFIER: US 6468981 B1
**** See image for Certificate of Correction ****
TITLE: Compositions and methods for targeting pharmaceutically active materials to cells containing androgen receptors

Brief Summary Text (21):
Polycationic salts useful for completing with nucleic acids include salts of cationic polyamines such polylysines, specifically poly-L-lysines, polyarginines, specifically poly-L-arginine, polyhistidine, and protamines.

First Hit Fwd Refs

☐ Generate Collection

L7: Entry 16 of 24 File: USPT Oct 22, 2002

DOCUMENT-IDENTIFIER: US 6468981 B1
** See image for Certificate of Correction **
TITLE: Compositions and methods for targeting pharmaceutically active materials to cells containing androgen receptors

Brief Summary Text (21):
Polycationic salts useful for completing with nucleic acids include salts of cationic polyamines such polylysines, specifically poly-L-lysines, polyarginines, specifically poly-L-arginine, polyhistidine, and protamines.

First Hit

Generate Collection Print

L7: Entry 14 of 24 File: PGPB Jul 5, 2001

PGPUB-DOCUMENT-NUMBER: 20010006817
PGPUB-FILING-TYPE: new-utility
DOCUMENT-IDENTIFIER: US 20010006817 A1

TITLE: CELL DELIVERY COMPOSITIONS

PUBLICATION-DATE: July 5, 2001

US-CL-CURRENT: 435/440; 435/325, 435/455, 435/456, 435/458, 435/6, 435/69.1, 435/91.1, 514/44, 530/300, 530/350, 536/23.1

APPL-NO: 09/ 251783 [PALM]
DATE FILED: February 17, 1999
CONTINUED PROSECUTION APPLICATION: CPA

RELATED-US-APPL-DATA:
Application is a non-provisional-of-provisional application 60/075272, filed February 19, 1998,

PRIORITY INFORMATION

[0001] This application claims priority to the co-pending provisional application No. 60/075,272 entitled "Cell Delivery Compositions" filed on Feb. 19, 1998, which is incorporated in its entirety by reference.

First Hit

Generate Collection Print

L7: Entry 14 of 24 File: PGPB Jul 5, 2001

DOCUMENT-IDENTIFIER: US 20010006817 A1
TITLE: CELL DELIVERY COMPOSITIONS

Detail Description Paragraph:
[0040] Those of ordinary skill in the art will, using known techniques, be able to prepare any of a variety of polyhistidine/polylysine compositions that can readily be tested according to the teachings herein to identify those with desirable delivery characteristics. The compositions must have sufficient polyhistidine composition (including available proton acceptor sites and/or polycationic character) to lyse endosomes, and sufficient polylysine composition to bind to nucleic acids, and condense them if necessary. Thus, the inventive polyhistidine/polylysine composition may comprise any combination of polylysine with polyhistidine, polylysine with histidine, or lysine with polyhistidine, associated with one another covalently or otherwise, so long as the combination is biocompatible and has the endosomolytic and nucleic acid binding/packaging capabilities described herein. As one of ordinary skill in the art will realize, the entire composition (including the bound nucleic acid) must be small enough to be taken up into cells. As mentioned above, endosomal compartments can usually accept entities up to about 150 nm in size.

Detail Description Paragraph:
[0103] The ability of the packaging agent to bind DNA can be assessed by monitoring complex formation with DNA using gel electrophoresis. The mobility of DNA on the gel will be retarded by complex formation, and the absence of any mobility of DNA on the gel suggests the complexation of all of the DNA. Preferably, complexation of DNA and the cationic polymer occurs as a ratio of 1:1 DNA/cationic polymer, and most preferably at a ratio of 1:3 DNA/cationic polymer as shown in FIG. 13 and 14 for DNA transferrin-polylysine and DNA/G-pHis mixtures. FIG. 15 depicts the gel electrophoresis of DNA/p-His mixtures and shows complexation at a weight:weight ratio of 1:0.5 DNA/p-His. Condensing of plasmid DNA can also be monitored by observing the ethidium bromide exclusion. For example, if gluconylated polyhistidine is used as the cationic polymer, the gluconylated polyhistidine efficiently condenses DNA at pH 5 where the gluconylated polyhistidine is .about.45% protonated. DNA is not condensed as effectively, however, at pH 7.4 where gluconylated polyhistidine is .about.5% protonated, as shown in FIG. 11.

STIC Search Report
Biotech-Chem Library

STIC Database Tracking Number: 112371

TO: Dave Nguyen **Location: rem2d31** **Art Unit: 1623** Jan 22, **2004** **Case Serial Number: 10/018103**	**From: P. Sheppard** **Location: Remsen Building** **Phone: (571) 272-2529** **sheppard@uspto.gov**

Search Notes

112371

STIC-Biotech/ChemLib

From: Page, Thurman
Sent: Saturday, January 17, 2004 11:39 AM
To: STIC-Biotech/ChemLib
Cc: Nguyen, Dave; Page, Thurman
Subject: FW: Rush Search request 10/018,103

Importance: High

RECEIVED
JAN 20 2004
(STIC)

RUSH SEARCH APPROVED

Thurman K. Page
SPE Art Units 1615 & 1616
Technology Center 1600

-----Original Message-----
From: Nguyen, Dave
Sent: Friday, January 16, 2004 9:17 PM
To: Page, Thurman
Cc: STIC-Biotech/ChemLib
Subject: Rush Search request 10/018,103

THis case is due this bi-week. Please rush. Please do a polypeptide/peptide search on SEQ ID NOS: 4-6.

Thanks,
Dave Nguyen
Art Unit: 1632
Ramsen Building
2D31
571-272-0731

Searcher: Sheppard
Phone:
Location:
Date Picked Up:
Date Completed: 1/22/04
Searcher Prep/Review:
Clerical:
Online time:

TYPE OF SEARCH:
NA Sequences:
AA Sequences:
Structures:
Bibliographic:
Litigation:
Full text:
Patent Family:
Other:

VENDOR/COST (where applic.)
STN:
DIALOG:
Questel/Orbit:
DRLink:
Lexis/Nexis:
Sequence Sys.:
WWW/Internet:
Other (specify):